Featured Research

from universities, journals, and other organizations

New therapy shows promise for treating cardiovascular disease

Date:
October 31, 2011
Source:
Wake Forest Baptist Medical Center
Summary:
A new therapy being studied in non-human primates is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.

A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.

Related Articles


Supported by the National Institutes of Health and the Canadian Institutes of Health Research, the preclinical findings appear in this week's issue of the journal Nature.

"The study was conducted because there is a very strong inverse correlation between the amount of HDL (good cholesterol) and heart disease," said co-principal investigator Ryan Temel, Ph.D., an assistant professor of pathology and lipid sciences at Wake Forest Baptist. "The higher your level of HDL, the lower your risk of developing cardiovascular disease. Currently, however, there are few therapies that significantly raise HDL."

While there are several effective therapies available on the market for lowering LDL, or bad cholesterol, modern medicine has yet to find a good way to raise HDL, Temel said. "Even if you take a statin or some other therapy to lower your LDL, the risk of having coronary heart disease is still around 50 percent. There's clearly a lot of room left for improvement."

Temel and colleagues from NYU Langone Medical Center and Regulus Therapeutics Inc., a biopharmaceutical company, are studying a new drug that targets microRNA-33 (miR-33). MiR-33 is a small RNA molecule that reduces HDL and increases triglyceride production. In previous studies in mice, the drug has been effective in promoting atherosclerotic plaque regression and increasing HDL.

For the current study, researchers tested the drug, anti-miR-33, in non-human primates and found that it increased HDL cholesterol and lowered triglycerides. Non-human primates were selected this time because rodents only express one form of miR-33 -- miR-33a -- while humans and non-human primates have two types of miR-33 -- miR-33a and miR-33b.

In the study, use of the drug resulted in a maximum HDL cholesterol increase of 50 percent after eight weeks that was sustained throughout the remainder of the 12-week study. Anti-miR-33a/b treatment in the non-human primate model also increased the expression of miR-33 target genes involved in fatty acid breakdown resulting in suppressed triglyceride levels, a finding not previously observed in mice. The decrease in triglycerides was apparent after four weeks and reached a maximum reduction of 50 percent.

This pre-clinical study was the first to demonstrate that inhibiting miR-33a/b has a significant and sustained effect on both circulating HDL and plasma triglyceride levels, Temel said.

These findings indicate that miR-33a and miR-33b are key regulators of cholesterol and fatty acid metabolism, Temel added, and that an anti-miR-33 approach could directly impact atherosclerosis, as well as address important cardiovascular risk factors such low HDL and high triglycerides.

The researchers will next evaluate whether the drug has the ability to stimulate cholesterol movement out of the arteries, where it has accumulated and formed atherosclerotic lesions.

"Coronary artery disease is the number one killer of people in the United States," Temel said. "It's a very big problem. The ideal therapy would not only reduce cholesterol accumulation in the arteries by lowering bad cholesterol but also increase the removal of existing cholesterol in the arteries by elevating good cholesterol. The combination of a statin and anti-miR-33 could potentially be this therapy. While there is still a lot of work that needs to be done with this drug before it can ever be used in humans, anti-miR-33 is showing strong potential as a new therapy for reducing coronary heart disease risk."


Story Source:

The above story is based on materials provided by Wake Forest Baptist Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Katey J. Rayner, Christine C. Esau, Farah N. Hussain, Allison L. McDaniel, Stephanie M. Marshall, Janine M. van Gils, Tathagat D. Ray, Frederick J. Sheedy, Leigh Goedeke, Xueqing Liu, Oleg G. Khatsenko, Vivek Kaimal, Cynthia J. Lees, Carlos Fernandez-Hernando, Edward A. Fisher, Ryan E. Temel, Kathryn J. Moore. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature, 2011; 478 (7369): 404 DOI: 10.1038/nature10486

Cite This Page:

Wake Forest Baptist Medical Center. "New therapy shows promise for treating cardiovascular disease." ScienceDaily. ScienceDaily, 31 October 2011. <www.sciencedaily.com/releases/2011/10/111028115350.htm>.
Wake Forest Baptist Medical Center. (2011, October 31). New therapy shows promise for treating cardiovascular disease. ScienceDaily. Retrieved December 17, 2014 from www.sciencedaily.com/releases/2011/10/111028115350.htm
Wake Forest Baptist Medical Center. "New therapy shows promise for treating cardiovascular disease." ScienceDaily. www.sciencedaily.com/releases/2011/10/111028115350.htm (accessed December 17, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, December 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Flu Outbreak Closing Schools in Ohio

Flu Outbreak Closing Schools in Ohio

AP (Dec. 17, 2014) A wave of flu illnesses has forced some Ohio schools to shut down over the past week. State officials confirmed one pediatric flu-related death, a 15-year-old girl in southern Ohio. (Dec. 17) Video provided by AP
Powered by NewsLook.com
Yoga Could Be As Beneficial For The Heart As Walking, Biking

Yoga Could Be As Beneficial For The Heart As Walking, Biking

Newsy (Dec. 17, 2014) Yoga can help your weight, blood pressure, cholesterol and heart just as much as biking and walking does, a new study suggests. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins